Srna

Self-amplifying RNA (saRNA or Replicons) Vaccines Patent Landscape Report 2023 with IP Profiles of Key Players - AlphaVax, BioNTech, Gritstone bio, GSK, Janssen, Merck - Animal Health, & Novartis - ResearchAndMarkets.com

Retrieved on: 
Thursday, March 30, 2023
Biotechnology, Pharmaceutical, Health, Vaccine, Abstract, Database, Hepatitis, HIV, Vaccination, Gowers Review of Intellectual Property, Intellectual property, SARS-CoV-2, COVID-19, Cancer, SARS, Livestock, Srna, Research, Infection, IP, RNA, Messenger, SaRNA, Publication, Animal, Novartis, Patent, Traction, VRP, Microsoft Excel, EP, CNE, Risk management, Pharmaceutical industry, LNP

The "Self-amplifying RNA vaccines Patent Landscape Analysis 2023" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Self-amplifying RNA vaccines Patent Landscape Analysis 2023" report has been added to ResearchAndMarkets.com's offering.
  • Currently, there are 2 main types of mRNA vaccines: conventional non-amplifying mRNA and self-amplifying mRNA (saRNA or replicons).
  • The saRNA vaccine platform may have higher manufacturing productivity and lower cost per dose compared to mRNA vaccines.
  • Moreover, this innovative and less expensive therapy tends to apply to the veterinary area with treatments for companion animals and livestock.

Gatehouse Bio Announces Upcoming Presentation at RNA Leaders Europe Congress

Retrieved on: 
Monday, March 13, 2023
Biotechnology, Technology, Health, General Health, Pharmaceutical, Health Technology, Other Technology, Research, Software, Artificial Intelligence, Science, Disease, Biology, RNA, IPF, AI, Escherichia coli sRNA, Doctor of Philosophy, Srna, Bio, Idiopathic pulmonary fibrosis, Safety, Messenger, Therapy, Medical device, Pharmaceutical industry

Gatehouse Bio, a TechBio company utilizing AI to decode the landscape of small RNAs (sRNAs) and digitally design precision oligonucleotide therapeutics, announced today that its Chief Executive Officer, David W. Salzman, PhD, will present at the upcoming RNA Leaders Europe Congress , in Basel, Switzerland on March 15, 2023 at 12:20PM CET.

Key Points: 
  • Gatehouse Bio, a TechBio company utilizing AI to decode the landscape of small RNAs (sRNAs) and digitally design precision oligonucleotide therapeutics, announced today that its Chief Executive Officer, David W. Salzman, PhD, will present at the upcoming RNA Leaders Europe Congress , in Basel, Switzerland on March 15, 2023 at 12:20PM CET.
  • This has enabled Gatehouse Bio to identify patient subsets, predict the biological effect and safety of therapeutic intervention, and digitally design targeted oligonucleotide therapeutics.
  • Over the last two years, Gatehouse Bio has used Code-Breaker to analyze multiple diseases and identify hotspots where there is high isoform burden.
  • Gatehouse Bio is currently developing its lead targets into biomarker-guided precision therapies for the treatment of pulmonary, cardiac, neurological, and autoimmune diseases.

​​TrueLearn Acquires APEX Anesthesia Review, a Leading Training Platform for the Anesthesia Nursing Community

Retrieved on: 
Wednesday, December 14, 2022
Hospitals, Health Technology, Other Health, Other Education, Continuing, Training, Health, General Health, Education, CRNA, APEX, Learning, Nursing, Student, Medicine, Anesthesia, Growth, Crna, Srna, Licensure, Acquisition, Organization, Tutoring, Picmonic

TrueLearn , a leading healthcare digital learning and analytics platform, has expanded its footprint and platform capabilities through the acquisition of APEX Anesthesia Review (APEX).

Key Points: 
  • TrueLearn , a leading healthcare digital learning and analytics platform, has expanded its footprint and platform capabilities through the acquisition of APEX Anesthesia Review (APEX).
  • The addition of APEX expands TrueLearns presence in nursing, a market TrueLearn entered through the acquisition of Picmonic in 2021.
  • We see tremendous opportunity to support APEXs continued growth in nurse anesthesia and in other areas of advanced practice nursing.
  • TrueLearn is a leading digital learning and analytics platform that focuses on training healthcare professionals in the areas of medicine, nursing and therapy.

sRNAlytics Receives FDA Support for AI-Powered Pathway Analytics Platform

Retrieved on: 
Thursday, February 28, 2019
Health, Biotechnology, Pharmaceutical, FDA, Medicine, Clinical medicine, Health, Biomarkers, Clinical trial, Srna

The use of objective biomarkers to assess Huntingtons Disease in clinical trials will enable us to more accurately determine if treatments are effective.

Key Points: 
  • The use of objective biomarkers to assess Huntingtons Disease in clinical trials will enable us to more accurately determine if treatments are effective.
  • In this recent study, sRNAlytics used their sRNA-FIND platform to discover small RNA biomarkers in the brain tissue of deceased Huntingtons patients.
  • sRNAlytics is initiating partnerships with Huntingtons drug developers to identify new efficacy and patient selection markers using sRNA-FIND.
  • Receiving the Letter of Support is a major milestone in the development of our platform.